Published in J Exp Med on September 02, 2002
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med (2011) 3.59
The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med (2011) 2.04
Immune regulation of cancer. J Clin Oncol (2010) 1.99
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 1.42
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol (2016) 1.41
IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest (2013) 1.36
CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther (2010) 1.33
Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res (2009) 1.25
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol (2011) 1.24
Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell (2011) 1.22
A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma. Br J Cancer (2004) 1.13
Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol (2006) 1.04
Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res (2008) 1.03
Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. J Immunol (2008) 1.01
Gadd45b and Gadd45g are important for anti-tumor immune responses. Eur J Immunol (2009) 1.00
Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients. PLoS One (2009) 1.00
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunol Immunother (2008) 0.98
Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine. Mol Immunol (2008) 0.98
The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem (2011) 0.97
Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest (2004) 0.95
Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res (2008) 0.94
Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci (2009) 0.92
Role of immunotherapy for renal cell cancer in 2011. J Natl Compr Canc Netw (2011) 0.91
Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res (2014) 0.91
Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Cancer J (2013) 0.90
Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother (2012) 0.89
Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients. Front Oncol (2014) 0.89
Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol (2009) 0.89
Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics (2006) 0.88
Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines. J Clin Immunol (2004) 0.88
HLA-DR+ immature cells exhibit reduced antigen-presenting cell function but respond to CD40 stimulation. Neoplasia (2005) 0.88
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med (2012) 0.87
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin Immunol (2009) 0.86
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Proc Natl Acad Sci U S A (2016) 0.85
Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses. PLoS One (2014) 0.85
The unfavorable effect of the A allele of the vitamin D receptor promoter polymorphism A-1012G has different mechanisms related to susceptibility and outcome of malignant melanoma. Dermatoendocrinol (2009) 0.84
Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology (2012) 0.84
IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age. Nat Commun (2015) 0.84
Dysregulation of anti-tumor immunity by the matrix metalloproteinase-2. Oncoimmunology (2012) 0.83
Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs (2009) 0.83
Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol Invest (2012) 0.83
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clin Dermatol (2013) 0.81
A top-down view of the tumor microenvironment: structure, cells and signaling. Front Cell Dev Biol (2015) 0.81
A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. J Immunother Cancer (2014) 0.81
Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo. Int J Oncol (2011) 0.81
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother (2011) 0.80
Interferon-gamma-induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells. Int J Biol Sci (2012) 0.80
The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells. J Immunother Cancer (2014) 0.79
Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1. J Immunol (2010) 0.79
Tumor-induced dysfunction in T lymphocytes: increased sensitivity to apoptosis. Urologe A (2004) 0.78
UPDATE ON VACCINE DEVELOPMENT FOR RENAL CELL CANCER. Open Access J Urol (2010) 0.77
Immune checkpoint blockade and interferon-α in melanoma. Semin Oncol (2015) 0.77
A gender factor in shaping T-cell immunity to melanoma. Front Oncol (2015) 0.77
DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand? Genet Vaccines Ther (2012) 0.77
How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy. J Immunother Cancer (2016) 0.77
Profound tumor-specific Th2 bias in patients with malignant glioma. BMC Cancer (2012) 0.76
Update on vaccine development for renal cell cancer. Open Access J Urol (2010) 0.76
Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma. Oncoimmunology (2016) 0.76
Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer. J Transl Med (2017) 0.75
miR-29b and miR-198 overexpression in CD8(+) T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. J Transl Med (2016) 0.75
Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother (2016) 0.75
An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs. Oncoimmunology (2016) 0.75
mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. Oncoimmunology (2016) 0.75
Molecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8(+) T-cell responses. Oncoimmunology (2014) 0.75
Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside. New Horiz Transl Med (2016) 0.75
Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. Curr Oncol Rep (2017) 0.75
Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy. Clin Transl Oncol (2017) 0.75
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Reciprocal control of T helper cell and dendritic cell differentiation. Science (1999) 7.28
The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02
Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol (1997) 5.95
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med (2001) 3.81
Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med (2001) 3.74
The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol (1998) 3.68
Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med (1997) 2.59
Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J Immunol (2002) 2.16
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med (1994) 2.01
Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol (2001) 1.95
Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med (1999) 1.82
Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res (2001) 1.82
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med (1999) 1.67
A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer (2001) 1.52
Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol (1999) 1.47
The role of IL4 and IL5: characterization of a distinct helper T cell subset that makes IL4 and IL5 (Th2) and requires priming before induction of lymphokine secretion. Immunol Rev (1988) 1.44
The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol (2000) 1.43
Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology (2001) 1.30
MHC antigens in human melanomas. Semin Cancer Biol (1991) 1.28
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A (2000) 1.19
Cytokine fields and the polarization of the immune response. Trends Immunol (2001) 1.16
A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol (1998) 1.16
Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. J Invest Dermatol (2000) 1.15
The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors. Immunol Res (1995) 1.12
gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br J Cancer (2001) 1.02
T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol (1997) 0.99
Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother (1995) 0.98
Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer (1999) 0.97
Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo. J Immunol (2000) 0.94
Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Int J Cancer (1994) 0.94
Expression of MAGE genes in osteosarcoma. J Orthop Res (1997) 0.91
Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother (2001) 0.91
Detection of biotinylated cell surface receptors and MHC molecules in a capture ELISA: a rapid assay to measure endocytosis. J Immunol Methods (1998) 0.90
MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma. Melanoma Res (2000) 0.89
Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+ T cells in a murine model implanted with B16 melanoma. Cell Immunol (2000) 0.87
Melanoma vaccines: the paradox of T cell activation without clinical response. Cancer Chemother Pharmacol (2000) 0.86
Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. J Immunol Methods (2002) 0.85
Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Mol Med Today (1997) 0.84
CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer Metastasis Rev (1999) 0.84
MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer (1996) 0.82
Is poor prognosis really related to HLA-DR expression by malignant melanoma cells? Histopathology (1992) 0.81
Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: correlation with clinical and histopathological data. Neoplasma (1999) 0.79
The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes. J Mol Med (Berl) (1998) 0.79
Analysis of TH1 and TH2 cells by intracellular cytokine detection with flow cytometry in patients with ovarian cancer. Gynecol Obstet Invest (2000) 0.78
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med (2005) 7.83
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 5.10
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis (2008) 4.47
Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40
Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol (2006) 3.95
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer (2004) 3.46
Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int (2014) 3.40
The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol (2004) 3.30
Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 3.00
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem (2004) 2.90
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer (2009) 2.78
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. J Am Soc Nephrol (2009) 2.70
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50
Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol (2006) 2.50
Regenerative potential of embryonic renal multipotent progenitors in acute renal failure. J Am Soc Nephrol (2007) 2.42
Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol (2003) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Autoreactive T cells in healthy individuals. J Immunol (2004) 2.29
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res (2010) 2.26
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer (2007) 2.25
Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med (2008) 2.25
Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol (2006) 2.24
Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol (2008) 2.21
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol (2005) 2.18
Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol (2003) 2.17
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res (2007) 2.15
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol (2005) 2.05
Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. J Allergy Clin Immunol (2011) 2.04
High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol (2007) 2.01
Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes (2002) 2.01
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol (2008) 2.00
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Chemotherapy for metastatic melanoma: time for a change? Cancer (2007) 1.99
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol (2007) 1.95
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res (2009) 1.90
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol (2008) 1.87
Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev (2002) 1.84
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol (2006) 1.83
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79
Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol (2009) 1.79
Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int (2004) 1.79
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med (2005) 1.76
Retracted Human renal stem/progenitor cells repair tubular epithelial cell injury through TLR2-driven inhibin-A and microvesicle-shuttled decorin. Kidney Int (2013) 1.75
Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol (2012) 1.73
A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis (2007) 1.73
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer (2008) 1.70
F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol (2003) 1.70
Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet (2012) 1.69
HLA class II-restricted CD4+ T cell responses directed against influenza viral antigens postinfluenza vaccination. J Immunol (2003) 1.69
Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med (2006) 1.67
HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in celiac disease. J Clin Invest (2006) 1.66
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation (2011) 1.66
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol (2007) 1.66
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One (2007) 1.65
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64
Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med (2007) 1.64
Systemic inflammation, metabolic syndrome and progressive renal disease. Nephrol Dial Transplant (2009) 1.63
Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol (2008) 1.63